Significantly increased quality and lower manufacturing costs for long template mRNAs San Diego, Calif. March 26, 2025 – Primrose Bio, Inc. (“Primrose”), a company developing proprietary therapeutic manufacturing technologies, announces the launch of Prima RNApols™... Primrose Bio, Inc. (“Primrose”), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. (“SIIPL”), the world’s largest vaccine manufacturer, today announced a collaboration to develop a novel multi-antigen... Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced... Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a... The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has IP and know how in vaccine... SAN DIEGO, Sept. 18, 2023 /PRNewswire/ -- Primrose Bio, Inc., a stand-alone private biotechnology company focused on developing state-of-the-art discovery and production systems for protein and nucleic acid medicines, has been established as a... Primrose Bio Launches Prima RNApols™ ExTend, an RNA Polymerase for Long-Template mRNA Manufacturing
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine
Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
Introducing Primrose Bio: Enabling Innovative Therapeutic Discovery and Manufacturing
Ligand signed a purchase and sale agreement with Primrose Bio and made an investment of $15m. The cross-pollination of platforms enables the San Diego-based company to create a novel way of enhancing productivity to enable the next generation of biological therapeutics
Advancing the manufacture of protein and nucleic acid-based biologic vaccines and therapeutics
BPI News: Primrose Bio Blossoms from Pelican and Primordial Genetics Merger